Evaxion A/S Files October 2025 Form 6-K

Ticker: EVAX · Form: 6-K · Filed: 2025-10-30T00:00:00.000Z

Sentiment: neutral

Topics: regulatory-filing, 6-K, biotechnology

TL;DR

Evaxion A/S filed its October 6-K, standard procedure for foreign private issuers.

AI Summary

Evaxion A/S, a biotechnology company, filed a Form 6-K on October 30, 2025, to report its activities for the month of October 2025. The company is incorporated in G7 and its fiscal year ends on December 31. Evaxion A/S is registered with the SEC under file number 001-39950.

Why It Matters

This filing provides an update on Evaxion A/S's regulatory activities, which is important for investors to stay informed about the company's compliance and reporting status.

Risk Assessment

Risk Level: low — This filing is a routine report of foreign private issuer activities and does not contain significant new financial or operational information.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer would be required to make public in its home country, or that it may be required to disclose or file with any stock exchange on which its securities are traded.

What is Evaxion A/S's SEC file number?

Evaxion A/S's SEC file number is 001-39950.

What is the reporting period for this Form 6-K?

The reporting period for this Form 6-K is the month of October 2025.

What is Evaxion A/S's primary business classification?

Evaxion A/S's primary business classification is 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with SIC code 2836.

Does Evaxion A/S file annual reports under Form 20-F?

Yes, Evaxion A/S indicates it files annual reports under cover of Form 20-F.

From the Filing

0001171843-25-006800.txt : 20251030 0001171843-25-006800.hdr.sgml : 20251030 20251030081505 ACCESSION NUMBER: 0001171843-25-006800 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20251030 FILED AS OF DATE: 20251030 DATE AS OF CHANGE: 20251030 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evaxion A/S CENTRAL INDEX KEY: 0001828253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39950 FILM NUMBER: 251432346 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM PROVINCE COUNTRY: G7 BUSINESS PHONE: 4552656554 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM PROVINCE COUNTRY: G7 FORMER COMPANY: FORMER CONFORMED NAME: Evaxion Biotech A/S DATE OF NAME CHANGE: 20201014 6-K 1 f6k_103025.htm FORM 6-K   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2025 Commission File Number: 001-39950 Evaxion A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]      Form 40-F [   ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.  --> INCORPORATION BY REFERENCE This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Press Release On October 30, 2025, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion raises $7.2 million, extending cash runway to second half of 2027". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K. Exhibits  Exhibit No.   Description       99.1   Evaxion raises $7.2 million, extending cash runway to second half of 2027 SIGNATURES Pursuant to

View on Read The Filing